Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome

Rheumatology

Volumn 46, Issue 7, 2007, Pages 1102-1106

  Fardet, Laurence ^a,b   Cabane, J ^a   Kettaneh, A ^a   Lebbe C ^c   Flahault, A ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL TENON   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Corticosteroids; Hypertension; Lipodystrophy; Metabolic syndrome

Indexed keywords

CHOLESTEROL; CORTICOSTEROID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISOLONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; GIANT CELL ARTERITIS; GLUCOSE BLOOD LEVEL; HISTIOCYTOSIS; HUMAN; HYPERTENSION; INCIDENCE; LIPODYSTROPHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SARCOIDOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS;

ADRENAL CORTEX HORMONES; ADULT; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; LIPODYSTROPHY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TRIGLYCERIDES;

EID: 34447333143     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem062     Document Type: Article

References (43)

1. Horber FF, Zurcher RM, Herren H, Crivelli MA, Robotti G, Frey FJ. Altered body fat distribution in patients with glucocortiooid treatment and in patients on long-term dialysis. Am J Clin Nutr 1986;43:758-69.
2. Nordborg E, Schaufelberger C, Bosaeus I. The effect of glucocorticoids on fat and loan tissue masses in giant call arteritis. Scand J Rheumatol 1998;27;106-11.
3. Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis Chest 1965;48:287-90.
4. Bar-Meir S, Chowers Y, Levy A et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998;115;835-40.
5. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41;209-14.
6. Covar RA, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk factors associated with glucooorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000;106:651-9.
7. Jover A Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-14.
8. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hypertipidaemia, and diabetes Mellitus: A cohort study. Lancet 1999;353:2093-9.
9. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9.
10. Herbst KL, Tannock LR, Deeb SS, Pumell JQ, Brunzell JD, Chait A. Kobberling type of familial partial lipodystrophy: An underrecognized syndrome. Diabetes Care 2003;26:1819-24.
11. Vantyghem MC, Pigny P, Maurage CA et al. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J Clin Endocrinol Metab 2004;89:5337-46.
12. Fardet L, Cabane J, Généreau T et al. Incidence and risk factors of lipodystrophy due to long-term (>3 months), high dosage (>20 mg/d) corticosteroid therapy. A prospective study, in press.
13. Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004;9:161-77.
14. Sutinen J, Kannisto K, Konsheninnikova E et al. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004;47:1660-71.
15. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study. Bmj 1996;313:344-6.
16. Fardet L, Kettaneh A, Tiev K et al. Digital photography as an operational tool for assessing corticosteroid-induced lipodystrophy, in press.
17. Boars M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
18. Capell HA, Madhok R, Hunter JA et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: Results of a randomised controlled trial. Ann Rheum Dis 2004;63:797-803.
19. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-oontrolled clinical trial. Ann Intern Med 2002;136:1-12.
20. Da Silva JA, Jacobs JW, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis 2006;65.285-93.
21. Morrison E, Crosbie D, Capell HA. Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology 2003;42:1247-50.
22. Bemasconi E, Boubaker K, Junghans C et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV cohort study. J Acquir Immune Defic Syndr 2002;31:50-5.
23. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids 1998;12:F51-8.
24. Palacios R, Merchante N, Macias J et al. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infectad patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 2006;11:529-35.
25. Yanovski JA, Miller KD, Kino T et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999;84:1925-31.
26. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations. Aids 1999;13:2251-60.
27. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62.
28. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
29. Thiebaut R, El-Sadr WM, Friis-Moller N et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005;10:811-23.
30. Gazzaruso C, Bruno R, Garzaniti A et al. Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003;21:1377-82.
31. Settler FR, Qian D, Louie S et al. Elevated blood pressure in subjects with lipodystrophy. Aids 2001;15;2001-10.
32. Nicholas PK, Kirksey KM, Corless IB, Kemppainen J. Lipodystrophy and quality of life in HIV: Symptom management issues. Appl Nurs Res 2005;18:55-8.
33. Ammassari A, Antinori A, Cozzi-Lepri A et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002;31(Suppl 3):S140-4.
34. Duran S, Saves M, Spire B et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 2001;15:2441-4.
35. Viraben R, Aquilina C. Indinavir-associated lipodystophy. Aids 1998;12:F37-9.
36. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cyrtokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
37. Festa A, D'Agostino R, Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
38. Jefferys DB, Lessof MH, Mattock MB. Corticosteroid treatment, serum lipids and coronary artery disease. Postgrad Med J 1980;56:491-3.
39. el-Shaboury AH, Hayes TM. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. Br Med J 1973;2:85-6.
40. Picado C, Deulofeu R, Lleonart R et al. Lipid and protein metabolism in asthma. Effects of diet and corticosteroid therapy. Allergy 1999;54:569-75.
41. Boers M, Nurmohamed MT, Doelman CJ et al. Influence of glucocorticoids and disease activity on total and high density lipoproteln cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5.
42. Souverein PC, Berard A, Van Staa TP et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004;90:859-65.
43. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.